表紙
市場調查報告書

全球肽治療市場、開發平台分析

Global Peptide Therapeutics Market & Clinical Pipeline Insight 2026

出版商 PNS Pharma 商品編碼 302551
出版日期 內容資訊 英文 1500 Pages
商品交期: 最快1-2個工作天內
價格
全球肽治療市場、開發平台分析 Global Peptide Therapeutics Market & Clinical Pipeline Insight 2026
出版日期: 2020年01月07日內容資訊: 英文 1500 Pages
簡介

本報告提供全球肽治療市場相關調查,市場概要,國家,適應症,各相位的開發平台分析,各肽類的肽開發平台,競爭情形,正在開發的肽,及上市肽等彙整資料,為您概述為以下內容。

第1章 簡介

第2章 作用機制:肽治療藥,肽疫苗及肽激素

第3章 全球肽治療藥市場概要

  • 目前的市場情勢
  • 全球肽開發平台概要

第4章 全球肽治療藥市場力學

  • 市場成長的促進要素
  • 商品化的課題

第5章 全球肽治療藥市場展望

第6章 環狀肽的開發平台:國家,適應症,各相位

  • 到預註冊為止的前臨床課程

第7章 雙勝肽:國家,適應症,各相位

  • 到預註冊為止的前臨床課程

第8章 縮酚酸肽:國家,適應症,各相位

  • 到第三階段為止的研究

第9章 醣勝肽:國家,適應症,各相位

  • 到第三階段為止的前臨床課程

第10章 胰島素的開發平台:國家,適應症,各相位

  • 到登記為止的前臨床課程

第11章 脂勝肽:國家,適應症,各相位

  • 到第三階段為止的研究

第12章 利鈉肽:國家,適應症,各相位

  • 到第三階段為止的前臨床課程

第13章 神經肽:國家,適應症,各相位

  • 到第二階段為止的前臨床課程

第14章 寡肽:國家,適應症,各相位

  • 到預註冊為止的研究

第15章 類鴉片肽:國家,適應症,各相位

  • 到預註冊為止的前臨床課程

第16章 肽的開發平台:國家,適應症,各相位

  • 到登記為止的研究

第17章 複合肽的開發平台:國家,適應症,各相位

  • 到預註冊為止的研究

第18章 上市肽的開發平台:國家,適應症,各相位

第19章 競爭情形

  • Amgen
  • Amylin Pharmaceuticals
  • Apitope Technology
  • BioPartners
  • BiondVax Pharmaceuticals Ltd
  • Boehringer Ingelheim
  • Circassia
  • Corden Pharma (Peptisyntha)
  • Eli Lily
  • Galena Biopharmaceuticals
  • GlaxoSmithKline
  • Hyperion Therapeutics
  • ImmunoCellular Therapeutics
  • Ipsen
  • Lonza
  • Merck
  • NovoNordisk
  • Par Pharmaceuticals
  • PeptiDream
  • Roche
  • Sanofi
  • Tarix Pharmaceuticals

圖表清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

“Global Peptide Therapeutics Market & Clinical Pipeline Insight 2026” report highlights:

  • Global Peptide Therapeutics Market Opportunity: US$ 65 Billion
  • Cancer Peptide Therapeutics Market Opportunity: US$ 22 Billion
  • Insight Peptide Drugs in Clinical Trials: 807 Peptides Drugs
  • Clinical & Patent Insight on 197 Marketed Peptides
  • Peptide Clinical Pipeline Is Dominated by Cyclic Peptides: 46 Peptides
  • Peptides Clinical Trials Insight by Phase, Indication & Company
  • Future Peptide Therapeutics Market Outlook

“Global Peptide Therapeutics Market & Clinical Pipeline Insight 2026” report gives comprehensive insight on clinical and non-clinical parameters involved in the development of global peptide drug market. As per report findings, peptides have emerged as one of the important classes of therapeutic molecules which have been developed by varied pharmaceutical and biotech companies in order to attain a targeted drug discovery for several ailments. Currently, there are more than 800 peptide drugs in clinical pipeline and 197 peptide based drugs commercially available in the market.

"Oncology Segment Will Continue To Dominate The Global Peptide Therapeutics Market In Terms Of Revenue Opportunity & Clinical Pipeline"

From the last several decades, therapeutic peptides and proteins have risen as potential drug candidate. Many companies are specializing in their manufacturing, along with companies developing peptide based products ranging from new drug candidates to medical diagnostic devices. The massive increase in the cost and time span to develop a conventional drugs led researchers and pharmaceutical companies to develop new cost effective products based of synthetic peptide strategy, which led to development large number of peptides of medical importance.

The lower toxicity levels of peptides can be credited to both their lower instance of interaction with other molecules not of interest and also to their ease of metabolism into their component amino acid residues. Pharmaceutical companies are attracted towards the peptides due to ease of manufacturing. In contrast to the old trial and error routines, nowadays the process starts with a clear understanding of the disease on a molecular level and based over the hypotheses of drug outcome, new drugs are designed.

The necessity of peptides as new innovative drug development has also been raised by the property of peptides being bioactive as considered one of the major interests of pharmaceuticals. As compared to synthetic substances peptides degrade into their component proteinogenic amino acid without leading to toxic metabolites. Furthermore, a disadvantage can sometimes be an advantage as peptides possess short half-lives which make them costly on one hand but advantage is less accumulation in the body.

"Global Peptide Drug Market Is Projected To Surpass US$ 60 Billion By 2026 Driven By Strong Clinical Pipeline & Favorable Commercialization Parameters "

In reference to these favorable attributes peptide drug market is flourishing and several peptide based therapeutics have been commercialized. With enhanced technologies, the prospects of the peptide drugs are getting influential day by day and new peptides are being discovered to be developed as peptide drug. Peptide therapeutics is completely different from the traditional way and may open a new window for finding completely new peptide drugs. Also, bioinformatics and systematic biological approaches help in searching for potential peptide drug candidates based on the knowledge and data.

The future potential of expanding peptide therapeutic market is contributed towards the characteristics like safety, targeted drug delivery and high specificity. Especially for illnesses requiring prolonged therapy, peptides have a competitive advantage over conventional small molecule drugs. Due to their extremely high specificity for their intended target, in combination with the fact that they are extra cellularly active, much lower amounts can be formulated.

Table of Contents

1. Introduction to Peptide Therapeutics

  • 1.1. Overview & Historical Development
  • 1.2. Why We Need Peptide Therapeutics?

2. Foundation of Peptide Therapeutics

  • 2.1. Screening of Novel Peptide Molecules
  • 2.2. Production of Therapeutic Peptides
  • 2.3. Regulation over Peptide Therapeutics

3. Key Aspects in Peptide Drug Development

  • 3.1. Approaches to Overcome Peptide Associated Limitations
    • 3.1.1. Terminal Protection
    • 3.1.2. Non-Chemical Modifications
    • 3.1.3. Synthetic Amino Acid Substitution & Backbone Modification
    • 3.1.4. Computational Modifications for Improving Aqueous Solubility & Membrane Permeability
  • 3.2. High-Throughput Screening (HTS) for New Peptide Entity

4. Peptide Therapeutics over Traditional Molecules

  • 4.1. Peptides v/s Biological Proteins
  • 4.2. Peptides v/s Small Molecules

5. Global Peptide Therapeutics Market Scenario

  • 5.1. Market Overview
  • 5.2. Market by Region
    • 5.2.1. North America
    • 5.2.2. Europe
    • 5.2.3. Asia
  • 5.3. Peptide Therapeutic Market Segmentation by Application
    • 5.3.1. Peptides in Imaging
    • 5.3.2. Peptides in Diseases
  • 5.4. Market by Route of Administration
    • 5.4.1. Current Scenerio
    • 5.4.2. Current Trends over Approved Peptide Products

6. Global Peptide Oncology Thereupetics Market Scenario

  • 6.1. Market Overview
  • 6.2. Peptide Oncology Drug Market - Regional Segmentation

7. Cancer Peptides Drug Cost, Dosage & Patent Insight

  • 7.1. Firmagon (Degarelix)
  • 7.2. Mepact (Mifamurtide)
  • 7.3. Zoladex (Goserelin)
  • 7.4. Eligard (Leuprolide)
  • 7.5. Lupron (Leuprolide Acetate)
  • 7.6. Plenaxis (Abarelix)
  • 7.7. Trelstar (Treptorelin)
  • 7.8. Decapeptyl SR (Treptorelin Acetate or Pamoate)
  • 7.9. Octreotide
  • 7.10. Sandostatin (Octeriotide Acetate)
  • 7.11. Velcade (bortizomib)
  • 7.12. Cosmegen (Dactinomycin)
  • 7.13. Somatuline Depot (lanreotide)
  • 7.14. Suprefact (Buserelin)
  • 7.15. Ninlaro (Ixazomib)
  • 7.16. Kyprolis (Carfilzomib)
  • 7.17. Gonax (Degarelix Acetate)

8. Peptide Therapeutics in Cardiovascular Disease

  • 8.1. Overview to Global Cardiovascular Diseases Burden
  • 8.2. Peptide Drugs in Cardiovascular Diseases - Availability & Cost Analysis
  • 8.3. Cardiac Peptide Therapeutics - Sales Analysis

9. Peptide Therapeutics in Metabolic Disorder

  • 9.1. Overview to Global Metabolic Disorders Burden
  • 9.2. Peptide Drugs for Metabolic Disorders - Availability, Cost & Dosage Analysis
  • 9.3. Market of Metabolic Peptides

10. Peptide Therapeutics For Infections

  • 10.1. Overview to Infectious Diseases
  • 10.2. Global - HIV Infection Burden
  • 10.3. Commercially Available Anti-Infective Peptide Drugs
  • 10.4. Anti-Infectious Peptide Drugs - Regional & Sales Analysis

11. Peptide Therapeutics aganist CNS Disorders

  • 11.1. Overview to CNS Disorders
  • 11.2. Approaches for Developing Neuropeptide Drugs
  • 11.3. Opportunities for Neuropeptide Drug Market

12. Global Peptides Drug Clinical Insight by Type

  • 12.1. Dipeptides
  • 12.2. Cyclic Peptides
  • 12.3. Depsipeptides
  • 12.4. Glucagon-Like Peptide
  • 12.5. Glycopeptides
  • 12.6. Insulin
  • 12.7. Lipopeptides
  • 12.8. Natriuretic Peptides
  • 12.9. Neuropeptides
  • 12.10. Oligopeptides
  • 12.11. Opioid Peptides
  • 12.12. Peptide Homone
  • 12.13. Peptides
  • 12.14. Peptide Fragments
  • 12.15. Peptide Vaccine
  • 12.16. Multiple Peptides

13. Global Peptide Drug Market Dynamics - Challenges & Drivers

  • 13.1. Global Peptide Drug Market Drivers
  • 13.2. Challenges for Global Peptide Drug Market

14. Global Peptide Therapeutics Market Future Panorama

  • 14.1. Future Trends in Peptide Therapeutics
  • 14.2. Peptides Therapeutics Market Opportunities

15. Oligopeptides Clinical Pipeline By Company, Indication & Phase

  • 15.1. Preclinical
  • 15.2. Phase-I
  • 15.3. Phase-I/II
  • 15.4. Phase-II
  • 15.5. Phase-III
  • 15.6. Preregistration
  • 15.7. Registered
  • 15.8. Marketed

16. Insulin Clinical Pipeline By Company, Indication & Phase

  • 16.1. Unknown
  • 16.2. Research
  • 16.3. Preclinical
  • 16.4. Clinical
  • 16.5. Phase-I
  • 16.6. Phase-I/II
  • 16.7. Phase-II
  • 16.8. Phase-II/III
  • 16.9. Phase-III
  • 16.10. Preregistration
  • 16.11. Registered
  • 16.12. Marketed

17. Peptide Hormone Clinical Pipeline By Company, Indication & Phase

  • 17.1. Unknown
  • 17.2. Research
  • 17.3. Preclinical
  • 17.4. Clinical
  • 17.5. Phase-I
  • 17.6. Phase-I/II
  • 17.7. Phase-II
  • 17.8. Phase-III
  • 17.9. Preregistration
  • 17.10. Marketed

18. Peptide Clinical Pipeline By Company, Indication & Phase

  • 18.1. Unknown
  • 18.2. Research
  • 18.3. Preclinical
  • 18.4. Clinical
  • 18.5. Phase-I
  • 18.6. Phase-I/II
  • 18.7. Phase-II
  • 18.8. Phase-II/III
  • 18.9. Phase-III
  • 18.10. Preregistration
  • 18.11. Registered
  • 18.12. Marketed

19. Glucagon-Like Peptide Clinical Pipeline By Company, Indication & Phase

  • 19.1. Preclinical
  • 19.2. Clinical
  • 19.3. Phase-I
  • 19.4. Phase-II
  • 19.5. Phase-III
  • 19.6. Preregistration
  • 19.7. Marketed

20. Glycopeptide Clinical Pipeline By Company, Indication & Phase

  • 20.1. Preclinical
  • 20.2. Phase-I
  • 20.3. Phase-I/II
  • 20.4. Marketed

21. Multiple Peptide Clinical Pipeline By Company, Indication & Phase

  • 21.1. Research
  • 21.2. Preclinical
  • 21.3. Phase-I
  • 21.4. Phase-II
  • 21.5. Phase-II/III
  • 21.6. Phase-III
  • 21.7. Preregistration
  • 21.8. Registered
  • 21.9. Marketed

22. Peptide vaccine Clinical Pipeline By Company, Indication & Phase

  • 22.1. Preclinical
  • 22.2. Phase-I
  • 22.3. Phase-I/II
  • 22.4. Phase-II
  • 22.5. Phase-III
  • 22.6. Registered
  • 22.7. Marketed

23. Cyclic Peptide Clinical Pipeline By Company, Indication & Phase

  • 23.1. Unknown
  • 23.2. Research
  • 23.3. Preclinical
  • 23.4. Phase-I
  • 23.5. Phase-II
  • 23.6. Phase-II/III
  • 23.7. Phase-III
  • 23.8. Preregistration
  • 23.9. Registered
  • 23.10. Marketed

24. Peptide Fragment Clinical Pipeline By Company, Indication & Phase

  • 24.1. Research
  • 24.2. Preclinical
  • 24.3. Phase-I
  • 24.4. Phase-I/II
  • 24.5. Phase-II
  • 24.6. Phase-II/III
  • 24.7. Preregistration
  • 24.8. Registered
  • 24.9. Marketed

25. Dipeptide Clinical Pipeline By Company, Indication & Phase

  • 25.1. Preclinical
  • 25.2. Phase-I
  • 25.3. Phase-I/II
  • 25.4. Phase-II
  • 25.5. Phase-III
  • 25.6. Registered
  • 25.7. Marketed

26. Opioid peptide Clinical Pipeline By Company, Indication & Phase

  • 26.1. Phase-I/II
  • 26.2. Phase-II
  • 26.3. Preregistration
  • 26.4. Registered
  • 26.5. Marketed

27. Depsipeptide Clinical Pipeline By Company, Indication & Phase

  • 27.1. Preclinical
  • 27.2. Phase-I
  • 27.3. Registered
  • 27.4. Marketed

28. Natriuretic Peptide Clinical Pipeline By Company, Indication & Phase

  • 28.1. Research
  • 28.2. Phase-II
  • 28.3. Phase-III
  • 28.4. Marketed

29. Neuropeptide Clinical Pipeline By Company, Indication & Phase

  • 29.1. Research
  • 29.2. Preclinical
  • 29.3. Phase-I
  • 29.4. Phase-I/II
  • 29.5. Phase-II
  • 29.6. Marketed

30. Pituitary Gonadotropin Clinical Pipeline By Company, Indication & Phase

  • 30.1. Unknown
  • 30.2. Preclinical
  • 30.3. Phase-I
  • 30.4. Phase-II
  • 30.5. Phase-III
  • 30.6. Marketed

31. Lipopeptide Clinical Pipeline By Company, Indication & Phase

  • 31.1. Research
  • 31.2. Preclinical
  • 31.3. Phase-II
  • 31.4. Phase-III

32. Peptide Aptamer Clinical Pipeline By Company, Indication & Phase

  • 32.1. Preclinical
  • 32.2. Phase-I
  • 32.3. Phase-I/II
  • 32.4. Phase-III

33. Competitive Landscape

  • 33.1. Amgen
  • 33.2. Amylin Pharmaceuticals
  • 33.3. Apitope Technology
  • 33.4. BioPartners
  • 33.5. BiondVax Pharmaceuticals Ltd
  • 33.6. Boehringer Ingelheim
  • 33.7. Circassia
  • 33.8. Corden Pharma (Peptisyntha)
  • 33.9. Eli Lily
  • 33.10. Galena Biopharmaceuticals
  • 33.11. GlaxoSmithKline
  • 33.12. Hyperion Therapeutics
  • 33.13. ImmunoCellular Therapeutics
  • 33.14. Ipsen
  • 33.15. Lonza
  • 33.16. Merck
  • 33.17. NovoNordisk
  • 33.18. Par Pharmaceuticals
  • 33.19. PeptiDream
  • 33.20. Roche
  • 33.21. Sanofi
  • 33.22. Tarix Pharmaceuticals

List of Figures

  • Figure 2-1: Classification of Peptides by Sources
  • Figure 2-2: Screening Approaches of Novel Therapeutics peptides
  • Figure 2-3: Methods for Large Scale Production of Therapeutic Peptides
  • Figure 2-4: General Concept of Manufacturing of Peptide Drugs
  • Figure 2-5: Process of Peptide Therapeutics FDA Approval Path
  • Figure 3-1: Different Approaches Used for Overcoming Peptide Drugs Associated Limitations
  • Figure 4- 1: Peptides as a Cusp of Small Molecule Drug & Proteins
  • Figure 4- 2: Advantages of Peptide Drugs
  • Figure 5-1: Global - Imaging Technology Market by Usage (%), 2018
  • Figure 5-2: Healthcare Imaging Market Share by Company (%), 2018
  • Figure 5-3: Diagrammatic Representation of the Peptidic Probe
  • Figure 5-4: Distribution of Therapeutic Drugs Approved by FDA by Chemical Species
  • Figure 5-5: Global - Peptide Therapeutics Market Size by Clinical Indications, 2018
  • Figure 5-6: Global - Insulin Market Forecast (US$ Billion) 2018 - 2026
  • Figure 5-7: Therapeutic Peptide Based Drugs over Route of Administration
  • Figure 6-1: Global - Peptide Therapeutics Market Forecast (US$ Billion), 2018 - 2026
  • Figure 6-2: Global - Total Peptide Therapeutic Market Size vs. Oncological Peptide Therapeutic Market Size (US$ Billion), 2019
  • Figure 6-3: Global - Peptide Oncology Drugs Market Size (US$ Billion), 2018 - 2026
  • Figure 6-4: Peptide Oncology Market - Regional Market Share (%), 2018
  • Figure 7-1: Classification of Therapeutic Peptides
  • Figure 7-2: Frimagon - Years of Different Patent Issue
  • Figure 7-3: Frimagon - Expiration Year of Different Patents
  • Figure 7-4: Frimagon - Cost of 80mg & 120mg Supply of Powder for Subcutaneous Injection (US$), October'2019
  • Figure 7-5: Firmagon - Starting & Maintenance Dosage (mg)
  • Figure 7-6: Firmagon - Treatment Cost of Initial Month, Maintenance Month & Annually (US$), October'2019
  • Figure 7-7: Mepact - Recommended Number of Dose Administration/ Week for 12 & 24 Weeks Treatment
  • Figure 7-8: Germany - Mepact Full Treatment Cost for Children & Adults (US$ Millions), October'2019
  • Figure 7-9: Zoladex - Patent Issue & Expiration Year
  • Figure 7-10: Zoladex - Cost of 3.6mg & 10.8mg Implant (US$), October'2019
  • Figure 7-11: Zoladex - Recommended Dose for Prostate cancer Management on Monthly Basis (MG), October'2019
  • Figure 7-12: Zoladex - Annual Treatment Cost using 3.6mg & 10.8mg Implant (US$), October'2019
  • Figure 7-13: Eligard - Patent Issue & Expiration Year
  • Figure 7-14: Eligard - Cost of Different doses of Extended Release Subcutaneous Powder for Injection (US$), October'2019
  • Figure 7-15: Eligard - Recommended Dosage for Porstate Cancer on Monthly Basis (mg)
  • Figure 7-16: Eligard - Annual Treatment cost of Prostate Cancer using Different available Doses (US$), October'2019
  • Figure 7-17: Eligard - Recomended Dose for Treatment of Uterine Leiomyomata on Monthly Basis (mg), October'2019
  • Figure 7-18: Eligard - Cost Per Month & Full Treatment Cost of Uterine Leiomyomata using 7.5mg Dose (US$), October'2019
  • Figure 7-19: Lupron - Patent Issue & Expiration Year for Controlled Release Preparation
  • Figure 7-20: Lupron - Patent Issue & Expiration Year for Sustained Release Preparation
  • Figure 7-21: Lupron - Price for 7.5mg, 22.5mg, 30mg & 40mg Depot (US$), October'2019
  • Figure 7-22: Lupron - Recommended Dosage for Prostate Cancer Treatment on Monthly Basis (mg)
  • Figure 7-23: Lupron - Annual Treatment Cost of Prostate Cancer Treatment using Different Available Doses (US$), October'2019
  • Figure 7-24: Lupron - Recomended Dose for Treatment of Uterine Leiomyomata on Monthly Basis (mg), October'2019
  • Figure 7-25: Lupron - Cost per Month & Full Treatment Cost of Uterine Leiomyomata using 7.5mg Depot (US$), October'2019
  • Figure 7-26: Plenaxis - Number of Recommended Doses on Monthly Basis
  • Figure 7-27: Plenaxis - Initial, Maintenance & Full Treatment Cost (US$), October'2019
  • Figure 7-28: Trelstar - Patent Issue & Expiration Year
  • Figure 7-29: Trelstar - Cost for a Supply of 3.75mg, 11.25mg & 22.5mg Powder for Intramuscular Injection (US$), October' 2019
  • Figure 7-30: Trelstar - Recommended Dose for Prostate Cancer Treatment (mg), October'2019
  • Figure 7-31: Trelstar - Annual Treatment Cost using 3.75 mg, 11.25mg & 22.5mg Powder for Intramuscular Injection (US$), October'2019
  • Figure 7-32: Decapeptyl SR - Price for a Supply of 3mg, 11.25mg & 22.5mg Powder for Injection (US$), October'2019
  • Figure 7-33: Decapeptyl SR - Recommended Dosage for Prostate Cancer Treatment on Monthly Basis (mg)
  • Figure 7-34: Decapeptyl SR - Annual Treatment Cost of Prostate Cancer Treatment using Different Available Doses (US$), October'2019
  • Figure 7-35: Octreotide - Cost of Different Commercially Available mg/ml Doses of Octreotide for 10 ml Supply (US$), October'2019
  • Figure 7-36: Octreotide - Average Initial Dose for Treatment of Carcinoid Tumor & Vasoactive Intestinal Peptide Tumor (mg), October'2019
  • Figure 7-37: Sandostatin - Price for 10 Vial Supply & per Unit Price of 50mcg/ml Injectable Solution (US$), October'2019
  • Figure 7-38: Sandostatin - Price for 10 Vial Supply & per Unit Price of 100mcg/ml Injectable Solution (US$), October'2019
  • Figure 7-39: Sandostatin - Price for 10 Vial Supply & per Unit Price of 500mcg/ml Injectable Solution (US$), October'2019
  • Figure 7-40: Sandostatin - Mean Initial Dose for Treatment of Carcinoid Tumor & Vasoactive Intestinal Peptide Tumor (mg), October'2019
  • Figure 7-41: Velcade - 1st & 2nd Patent Issue & Expiration Year
  • Figure 7-42: Velcade - Price of 3.5mg Supply & Full Treatment Cost for Multiple myeloma (US$), October'2019
  • Figure 7-43: Cosmegen - Average Cost of once in 3 Week & once in 6 Week Treatment Cycle for Wilm's Tumor using 0.5mg Powder for Injection (US$), October'2019
  • Figure 7-44: Cosmegen - Treatment Cost of One Cycle & Full Treatment Cost of Rhabdomyosarcoma (US$), October'2019
  • Figure 7-45: Cosmegen - Treatment Cost of One Cycle & Full Treatment Cost of Ewing's Tumor (US$), October'2019
  • Figure 7-46: Cosmegen - Treatment Cost of One Cycle & Full Treatment Cost of Testicular Cancer (US$), October'2019
  • Figure 7-47: Cosmegen - Full Treatment Cost as Monotherapy & Combinational Therapy in Trophoblastic Disease (US$), October'2019
  • Figure 7-48: Cosmegen - Full Treatment Cost of Upper & lower Body Solid Tumor (US$), October'2019
  • Figure 7-49: Somatuline Depot - Patent Issue & Expiration Year
  • Figure 7-50: Somatuline Depot - Price of 60mg/0.2 ml Supply & Price per unit of Somatulin Depot Subcutaneous Solution (US$), October'2019
  • Figure 7-51: Somatuline Depot - Price of 90mg/0.3ml Supply & Price per unit of Somatulin Depot Subcutaneous Solution (US$), October'2019
  • Figure 7-52: Somatuline Depot - Price of 120mg/0.5ml Supply & Price per unit of Somatulin Depot Subcutaneous Solution (US$), October'2019
  • Figure 7-53: Somatuline Depot - Treatment cost of 1 Cycle & Annual Treatment Cost of GEP-NETs & Carcinoid Syndrome (US$), October'2019
  • Figure 7-54: Suprefact - Price of 6.3mg & 9.45mg Depot (US$), October'2019
  • Figure 7-55: Suprefact - Cost for a Supply of 1ml/ml Nasal Spray and Injectable solution (US$), October'2019
  • Figure 7-56: Suprefact Injection - Recommended Initial Dose & Final Dose For Prostate Cancer Treatment (mg/Day), October'2019
  • Figure 7-57: Suprefact Depot - Recommended Dose for Prostate Cancer Treatment on Monthly Basis (mg), October'2019
  • Figure 7-58: Suprefact Depot - Annual Prostate Cancer Treatment Cost (US$), October'2019
  • Figure 7-59: Ninlaro - Patent Issue & Expiration Year
  • Figure 7-60: Ninlaro - Price for 3 Capsule Supply & Price per Unit of Ninlaro Capsule (US$), October'2019
  • Figure 7-61: Ninlaro - Recommended Dose & Dose Reductions for Treatment of Multiple Myeloma (Mg/Week), October'2019
  • Figure 7-62: Ninlaro - Cost of 1 Treatment Cycle & Full Treatment Cost for Multiple Myeloma (US$), October'2019
  • Figure 7-63: Kyprolis - Issue & Expiration Year of Patents Assigned to Proteolix Inc.
  • Figure 7-64: Kyprolis - Issue & Expiration Year of Patent Assigned to Cydex Pharmaceuticals
  • Figure 7-65: Kyprolis - Issue & Expiration Year of Patents Assigned to Onyx Therapeutics
  • Figure 7-66: Kyprolis - Price of 10mg, 30mgg & 60mg Intraveneous Powder for Injection (US$), October'2019
  • Figure 7-67: Kyprolis - Initial Dose & Maintainence Dose for Treatment of Multiple Myeloma (mg/m2 Per Week)
  • Figure 7-68: Kyprolis - Initial Dose & Maintainence Dose as Monotherapy for Treatment of Multiple Myeloma (mg/m2 Per Week)
  • Figure 7-69: Gonax - Cost of 80mg & 120mg Supply of Powder for Subcutaneous Injection (US$), October'2019
  • Figure 7-70: Gonax - Starting & Maintenance Dosage (mg)
  • Figure 7-71: Gonax - Treatment Cost of Initial Month, Maintenance Month & Annually (US$), October'2019
  • Figure 8-1: Global - Cardiovascular Mortality (%), 2018
  • Figure 8-2: Cardiovascular Peptide Therapeutics - Cost Analysis (US$//Patient), 2018
  • Figure 8-3: Global - Angiomax Sales (US$ Million), 2018
  • Figure 8-4: Global - Integrilin Sales (US$ Million), 2016 & 2017
  • Figure 9-1: Global - Prevalence of Metabolic Disorders by Region (%), 2018
  • Figure 9-2: Layout of Metabolic Syndrome Leading to Several Diseases
  • Figure 9-3: Global - Top 10 Countries with Diabetes Burden (Million), 2030
  • Figure 9-4: Global - Obesity in Women & Men by Region (Million), 2018
  • Figure 9-5: US- GLP-1 Agonist Drugs Comparative Cost Analysis (US$), 2018
  • Figure 9-6: Lantus - Monthly Cost Comparison by Country (US$), 2018
  • Figure 9-7: Global - Metabolic Peptide Market Size (%), 2018
  • Figure 10-1: Global - Top 10 Leading Causes of Death
  • Figure 10-2: Global - Distribution of AIDS Affected Patients by Region (%), 2018
  • Figure 10-3: Fuzeon - Global Sales (US$ Millions), 2015 - 2017
  • Figure 11-1: US - Prevalence of Alzheimer's disease (Million)
  • Figure 11-2: Alzheimer Disease Market Size (%), 2018
  • Figure 12-1: Global - Total Peptides Clinical Pipeline by Phase (%), 2018 till 2024
  • Figure 12-2: Global Total Peptides Clinical Pipeline by Phase (Number), 2018 till 2024
  • Figure 12-3: Global - Dipeptides Clinical Pipeline by Phase (%),2019 till 2026
  • Figure 12-4: Global - Dipeptides Clinical Pipeline by Phase (Number), 2019 till 2026
  • Figure 12-5: Global - Cyclic Peptides Clinical Pipeline by Phase (%),2019 till 2026
  • Figure 12-6: Global - Cyclic Peptides Clinical Pipeline by Phase (Number), 2019 till 2026
  • Figure 12-7: Global - Depsipeptides Clinical Pipeline by Phase (%),2019 till 2026
  • Figure 12-8: Global - Depsipeptides Clinical Pipeline by Phase (Number), 2019 till 2026
  • Figure 12-9: Global - Glucagon-Like Peptide Clinical Pipeline by Phase (Number), 2019 till 2026
  • Figure 12-10: Global - Glucagon-Like Peptide Clinical Pipeline by Phase (%),2019 till 2026
  • Figure 12-11: Global - Glycopeptides Clinical Pipeline by Phase (%),2019 till 2026
  • Figure 12-12: Global - Glycopeptides Clinical Pipeline by Phase (Number), 2019 till 2026
  • Figure 12-13: Global - Insulin Clinical Pipeline by Phase (Number), 2019 till 2026
  • Figure 12-14: Global - Insulin Clinical Pipeline by Phase (%), 2019 till 2026
  • Figure 12-15: Global - Lipopeptides Clinical Pipeline by Phase (%),2019 till 2026
  • Figure 12-16: Global - Lipopeptides Clinical Pipeline by Phase (Number), 2019 till 2026
  • Figure 12-17: Global - Natriuretic Peptides Clinical Pipeline by Phase (%),2019 till 2026
  • Figure 12-18: Global - Natriuretic Peptides Clinical Pipeline by Phase (Number), 2019 till 2026
  • Figure 12-19: Global - Neuropeptides Clinical Pipeline by Phase (%),2019 till 2026
  • Figure 12-20: Global - Neuropeptides Clinical Pipeline by Phase (Number), 2019 till 2026
  • Figure 12-21: Global - Oligopeptides Clinical Pipeline by Phase (%),2019 till 2026
  • Figure 12-22: Global - Oligopeptides Clinical Pipeline by Phase (Number), 2019 till 2026
  • Figure 12-23: Global - Opioid Peptides Clinical Pipeline by Phase (%),2019 till 2026
  • Figure 12-24: Global - Opioid Peptides Clinical Pipeline by Phase (Number), 2019 till 2026
  • Figure 12-25: Global - Peptide Hormone Clinical Pipeline by Phase (Number), 2019 till 2026
  • Figure 12-26: Global - Peptide Hormone Clinical Pipeline by Phase (%),2019 till 2026
  • Figure 12-27: Global - Peptides Clinical Pipeline by Phase (%),2019 till 2026
  • Figure 12-28: Global - Peptides Clinical Pipeline by Phase (Number), 2019 till 2026
  • Figure 12-29: Global - Peptide Fragments Clinical Pipeline by Phase (%),2019 till 2026
  • Figure 12-30: Global - Peptide Fragments Clinical Pipeline by Phase (Number), 2019 till 2026
  • Figure 12-31: Global - Peptide Vaccine Clinical Pipeline by Phase (%),2019 till 2026
  • Figure 12-32: Global - Peptide Vaccine Clinical Pipeline by Phase (Number), 2019 till 2026
  • Figure 12-33: Global - Multiple Peptides Clinical Pipeline by Phase (%),2019 till 2026
  • Figure 12-34: Global - Multiple Peptides Clinical Pipeline by Phase (Number), 2019 till 2026
  • Figure 13-1: Illustration of Peptide Therapeutics Market Drivers
  • Figure 13-2: Major Challenges Faced by the Peptide Therapeutics
  • Figure 14-1: Global - Estimated Future Peptide Therapeutics Market Size by Clinical Indication (%), 2026
  • Figure 14-2: Global - Cancer Peptide Therapeutics Forecast (US$ Billion), 2018 - 2024
  • Figure 14-3: Future Trends of Peptide Therapeutics

List of Tables

  • Table 4-1: Comparative Differentiation between Peptide & Protein Drugs
  • Table 4-2: Comparative Analysis of Small Molecules & Peptide Drugs
  • Table 5-1: List of Approved Peptide Drugs Since 2000
  • Table 7-1: Peptide Based Drugs
  • Table 8-1: Approved Peptide Drugs for Cardiovascular Diseases
  • Table 9-1: Major Approved GLP-1 Peptide Drugs for Metabolic Disorders
  • Table 9-2: Layout of Insulin & its Analogs Cost in US
  • Table 10-1: Approved Drugs for Infections
  • Table 11-1: Brief Characterization of Some Neuroprotective Peptides
  • Table 11-2: Potential Targets for Peptide Based Therapies in CNS Disorders